These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 16247445)
21. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Duque-Afonso J; Yalcin A; Berg T; Abdelkarim M; Heidenreich O; Lübbert M Oncogene; 2011 Jul; 30(27):3062-72. PubMed ID: 21577204 [TBL] [Abstract][Full Text] [Related]
22. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037 [TBL] [Abstract][Full Text] [Related]
23. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia. Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217 [TBL] [Abstract][Full Text] [Related]
24. PIG7, transactivated by AML1, promotes apoptosis and differentiation of leukemia cells with AML1-ETO fusion gene. Liu J; Xing H; Chen Y; Wang L; Wang D; Rao Q; Tang K; Tian Z; He K; Wang M; Wang J Leukemia; 2012 Jan; 26(1):117-26. PubMed ID: 21836606 [TBL] [Abstract][Full Text] [Related]
25. MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Lasa A; Carnicer MJ; Aventín A; Estivill C; Brunet S; Sierra J; Nomdedéu JF Leukemia; 2004 Jul; 18(7):1231-7. PubMed ID: 15103390 [TBL] [Abstract][Full Text] [Related]
26. Transcriptional and epigenetic regulation of the GM-CSF promoter by RUNX1. Oakford PC; James SR; Qadi A; West AC; Ray SN; Bert AG; Cockerill PN; Holloway AF Leuk Res; 2010 Sep; 34(9):1203-13. PubMed ID: 20439113 [TBL] [Abstract][Full Text] [Related]
27. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Burel SA; Harakawa N; Zhou L; Pabst T; Tenen DG; Zhang DE Mol Cell Biol; 2001 Aug; 21(16):5577-90. PubMed ID: 11463839 [TBL] [Abstract][Full Text] [Related]
28. AML1 and AML1 fusion protein AML1-ETO in myeloid gene regulation and leukemogenesis. Zhang DE; Burel S; Zhou L; Hetherington CJ; Yuan Y Blood Cells Mol Dis; 2001; 27(2):368-76. PubMed ID: 11259158 [No Abstract] [Full Text] [Related]
29. Transcription of the AML1/ETO chimera is guided by the P2 promoter of the AML1 gene in the Kasumi-1 cell line. Markova EN; Kantidze OL; Razin SV Gene; 2012 Dec; 510(2):142-6. PubMed ID: 22995345 [TBL] [Abstract][Full Text] [Related]
30. AML1/ETO inhibits AML1/CCAAT-enhancer binding protein-alpha mediated activation of the CD11c promoter and represses CD11c expression in HL60 cells. Drescher B; Nagel S; Krauter J; Heidenreich O; Ganser A; Heil G Haematologica; 2003 Aug; 88(8):956-8. PubMed ID: 12935984 [No Abstract] [Full Text] [Related]
31. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. Nimer SD; Moore MA Oncogene; 2004 May; 23(24):4249-54. PubMed ID: 15156180 [TBL] [Abstract][Full Text] [Related]
32. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia. Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347 [TBL] [Abstract][Full Text] [Related]
33. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific M-CSF receptor promoter by PU.1. Li X; Vradii D; Gutierrez S; Lian JB; van Wijnen AJ; Stein JL; Stein GS; Javed A J Cell Biochem; 2005 Nov; 96(4):795-809. PubMed ID: 16149049 [TBL] [Abstract][Full Text] [Related]
34. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins. Lou J; Cao W; Bernardin F; Ayyanathan K; RauscherIII FJ; Friedman AD Oncogene; 2000 May; 19(22):2695-703. PubMed ID: 10851069 [TBL] [Abstract][Full Text] [Related]
35. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112 [TBL] [Abstract][Full Text] [Related]
36. Dominant negative effects of the AML1/ETO fusion oncoprotein. Fenske TS; Pengue G; Graubert TA Cell Cycle; 2005 Jan; 4(1):33-6. PubMed ID: 15611635 [TBL] [Abstract][Full Text] [Related]
37. TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expression. Asakura K; Uchida H; Miyachi H; Kobayashi H; Miyakawa Y; Nimer SD; Takahashi H; Ikeda Y; Kizaki M Mol Cancer Res; 2004 Jun; 2(6):339-47. PubMed ID: 15235109 [TBL] [Abstract][Full Text] [Related]
38. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells. Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846 [TBL] [Abstract][Full Text] [Related]
39. AML1-Evi-1 specifically transforms hematopoietic stem cells through fusion of the entire Evi-1 sequence to AML1. Takeshita M; Ichikawa M; Nitta E; Goyama S; Asai T; Ogawa S; Chiba S; Kurokawa M Leukemia; 2008 Jun; 22(6):1241-9. PubMed ID: 18337762 [TBL] [Abstract][Full Text] [Related]